Brief: Ascentage Pharma's MDM2-P53 Inhibitor APG-115 Granted Orphan Drug Designation By The FDA For The Treatment Of Gastric Cancer
14/09/2020 12:33
Sept 14 (Reuters) - Ascentage Pharma Group International
6855.HK :
* ASCENTAGE PHARMA'S MDM2-P53 INHIBITOR APG-115 GRANTED
ORPHAN
DRUG DESIGNATION BY THE FDA FOR THE TREATMENT OF GASTRIC CANCER
Source text for Eikon: ID:nPn2xhRdya
Further company coverage: 6855.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascentage Pharma International
See all newsBrief: Ascentage Pharma Group Says Lisaftoclax Granted Breakthrough Therapy Designation In China
China's Ascentage Pharma climbs as chairman buys shares on market
Brief: Ascentage Pharma Group International's Chairman Buys 38,630 Shares
Brief: Ascentage Pharma Group International Posts H1 Net Loss Attributable RMB816.7 Million
China's Ascentage Pharma H1 revenue rises 29% on Lisaftoclax ramp-up